# Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

> **NCT00474786** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 512 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** temsirolimus (Torisel)

## Key facts

- **NCT ID:** NCT00474786
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2012-01
- **Final completion:** 2013-01
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2013-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00474786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00474786, "Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00474786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*